{"id":"NCT01603056","sponsor":"ALK-Abell√≥ A/S","briefTitle":"Efficacy and Safety Trial of Pangramin SLIT HDM-mix in Subjects With House Dust Mite Induced Rhinitis","officialTitle":"A Randomised, Double-blind, Placebo-controlled Phase III Multicentre Clinical Trial Investigating the Efficacy and Safety of Pangramin SLIT HDM-mix in Chinese Population With House Dust Mite Induced Rhinitis With or Without Asthma.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-10","primaryCompletion":"2012-02","completion":"2012-02","firstPosted":"2012-05-22","resultsPosted":"2016-04-29","lastUpdate":"2016-04-29"},"enrollment":617,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Allergic Rhinitis"],"interventions":[{"type":"BIOLOGICAL","name":"Pangramin SLIT HDM mix.","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"PANGRAMIN SLIT HDM MIX","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Primary aim is to evaluate the efficacy of specific immunotherapy with Pangramin SLIT HDM-mix compared to placebo in the treatment of House Dust Mite (HDM) induced rhinitis with or without asthma.\n\nSublingual immunotherapy has been used during several years and has been shown to provide benefits compare to traditional subcutaneous treatment. This study will investigate if improvements in rhinitis symptoms and less use of symptomatic medication can be obtained as a consequence of being treated under specific immunotherapy.\n\nThis study aim also to contribute to the documentation of tolerability and safety profile of Pangramin HDM Mix.","primaryOutcome":{"measure":"The Change From Baseline in Rhinoconjunctivitis Symptoms Score at 11 - 12 Months Between the Actively Treated Patients and the Placebo Treated.","timeFrame":"Baseline: From V1 date(Week -8) to V2 date(Week 0); 11-12months: From V8 date(Week 44) to V9 date(Week 52).","effectByArm":[{"arm":"PANGRAMIN SLIT HDM MIX","deltaMin":-1.77,"sd":2.13},{"arm":"Placebo","deltaMin":-1.83,"sd":2.18}],"pValues":[{"comp":"OG000 vs OG001","p":"0.743"}]},"eligibility":{"minAge":"5 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":8},"locations":{"siteCount":1,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":402},"commonTop":["Rhinopharyngitis","Upper respiratory tract infection","Asthma","Cough","Bronchitis"]}}